BIOTECH
CLINICAL LABORATORIES

Hepatitis C Technical Bulletin

The Center for Disease Control and Prevention (CDC) recommends adapting automatic HCV reflex to an FDA-approved Nucleic Acid assay for the detection of HCV RNA following positive Hepatitis Antibody Test. This algorithm will advance patients toward hepatitis C treatment and improve patients health outcome.

The adoption of routine HCV reflexing is imperative as CDC released **new universal hepatitis C testing recommendations** among all adult aged 18 years and older and among all pregnant persons during every pregnancy.

Implementation of reflex Hepatitis C testing for positive HCV antibody to HCV RNA is also promoted by the Michigan Department of Health and Human Services (MDHHS). This initiative by MDHS will help to achieve HCV elimination by expanding access to HCV treatment based on confirmation of active infection and providing patients with lifesaving medications.

Effective April 7th 2021, Biotech Clinical Laboratory will implement a new algorithm for Hepatitis C testing. All **Hepatitis C positive antibody patients will be automatically reflexed to The Aptima HCV Quantitative real-time TMA test used for both detection and quantitation of hepatitis C virus (HCV) RNA** in fresh and frozen human serum from HCV-infected individuals.

If you have any questions, please contact Client Services at 248-912-1700 to speak with a Technologist or Technical Director.